To test this, we added the glutaminase inhibitor CB839 to RCC TIL culture conditions and found that it enhanced granzyme B production from CD8+ RCC TILs in a subset of patient samples (Supplemental Figure 5B). The gene discussed is GLS; the disease is renal cell carcinoma.